Literature DB >> 16648099

New therapeutic targets in cancer: the epigenetic connection.

Michel Herranz1, Manel Esteller.   

Abstract

Cancer is an epigenetic disease, a combination of DNA modifications, chromatin organization and variations in its associated proteins, configure a new entity that regulates gene function throughout methylation, acetylation and chromatin remodelling. Irregular de novo DNA methylation, mainly promoter hypermethylation, histone deacetylation or methylation are important means for the transcriptional repression of cancer-associated genes. Reverse these epigenetic processes restoring normal expression of malignancy- preventing-genes has consequently become a new therapeutic target in cancer treatment. Aberrant patterns of epigenetic modifications will be, in a near future, crucial parameters in cancer diagnosis, prognosis and therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16648099     DOI: 10.1007/BF02664934

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  33 in total

Review 1.  Ubiquitin enters the new millennium.

Authors:  C M Pickart
Journal:  Mol Cell       Date:  2001-09       Impact factor: 17.970

2.  Histone sumoylation is associated with transcriptional repression.

Authors:  Yuzuru Shiio; Robert N Eisenman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-24       Impact factor: 11.205

Review 3.  Histone modifications in corepressor functions.

Authors:  Judith K Davie; Sharon Y R Dent
Journal:  Curr Top Dev Biol       Date:  2004       Impact factor: 4.897

4.  Cancer. A deadly inheritance.

Authors:  B Vogelstein
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

5.  Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells.

Authors:  Ana Villar-Garea; Mario F Fraga; Jesus Espada; Manel Esteller
Journal:  Cancer Res       Date:  2003-08-15       Impact factor: 12.701

6.  DNA (cytosine-5)-methyltransferases in mouse cells and tissues. Studies with a mechanism-based probe.

Authors:  J A Yoder; N S Soman; G L Verdine; T H Bestor
Journal:  J Mol Biol       Date:  1997-07-18       Impact factor: 5.469

7.  Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine.

Authors:  Carvell T Nguyen; Daniel J Weisenberger; Mihaela Velicescu; Felicidad A Gonzales; Joy C Y Lin; Gangning Liang; Peter A Jones
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

8.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

9.  Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases.

Authors:  Maria F Paz; Susan Wei; Juan C Cigudosa; Sandra Rodriguez-Perales; Miguel A Peinado; Tim Hui-Ming Huang; Manel Esteller
Journal:  Hum Mol Genet       Date:  2003-07-15       Impact factor: 6.150

10.  Dependence of histone modifications and gene expression on DNA hypermethylation in cancer.

Authors:  Jill A Fahrner; Sayaka Eguchi; James G Herman; Stephen B Baylin
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

View more
  8 in total

1.  Identification and characterization of putative methylation targets in the MAOA locus using bioinformatic approaches.

Authors:  Elena Shumay; Joanna S Fowler
Journal:  Epigenetics       Date:  2010-05-05       Impact factor: 4.528

Review 2.  Bookmarking the genome: maintenance of epigenetic information.

Authors:  Sayyed K Zaidi; Daniel W Young; Martin Montecino; Andre J van Wijnen; Janet L Stein; Jane B Lian; Gary S Stein
Journal:  J Biol Chem       Date:  2011-03-24       Impact factor: 5.157

Review 3.  Gene expression regulation and cancer.

Authors:  M Dolore Delgado; Javier León
Journal:  Clin Transl Oncol       Date:  2006-11       Impact factor: 3.405

Review 4.  Targeting deregulated epigenetic control in cancer.

Authors:  Sayyed K Zaidi; Andre J Van Wijnen; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2013-11       Impact factor: 6.384

Review 5.  Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.

Authors:  Federico Andreoli; Arménio Jorge Moura Barbosa; Marco Daniele Parenti; Alberto Del Rio
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.310

Review 6.  Computer-aided Molecular Design of Compounds Targeting Histone Modifying Enzymes.

Authors:  Federico Andreoli; Alberto Del Rio
Journal:  Comput Struct Biotechnol J       Date:  2015-05-07       Impact factor: 7.271

7.  Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase / ERK-MMP-laminin5γ2 signaling pathway.

Authors:  Xiao Liu; Ji-Hui Wang; Shun Li; Lin-Lin Li; Min Huang; Yong-Hong Zhang; Yang Liu; Yuan-Tao Yang; Rui Ding; Yi-Quan Ke
Journal:  Cancer Sci       Date:  2015-06-18       Impact factor: 6.716

8.  Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion.

Authors:  C Ling; S Del Guerra; R Lupi; T Rönn; C Granhall; H Luthman; P Masiello; P Marchetti; L Groop; S Del Prato
Journal:  Diabetologia       Date:  2008-02-13       Impact factor: 10.122

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.